HUMAXX, NCT05908084: To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis |
|
|
| Recruiting | 3 | 150 | US | Acellular Tissue Engineered Vessel (ATEV), Human Acellular Vessel (HAV), AVF | Humacyte, Inc., IQVIA Biotech | End Stage Renal Disease (ESRD) | 10/26 | 10/27 | | |